GLP 1 Drug Biosimilar Market Size, Share, Trend Report 2026 to 2035

What is GLP 1 Drug Biosimilar Market Size?

GLP 1 Drug Biosimilar Market Size is valued at USD 3.40 Bn in 2025 and is predicted to reach USD 86.23 Bn by the year 2035 at a 40.0% CAGR during the forecast period for 2026 to 2035.

GLP 1 Drug Biosimilar Market Size, Share & Trends Analysis by Reference Biologic (Semaglutide Biosimilar, Liraglutide Biosimilar, Exenatide Biosimilar, Dulaglutide Biosimilar), by Formulation (Injectable Pen, Oral Tablet, Patch & Implant), by Distribution (Retail Pharmacy, Mail-Order & Specialty Pharmacy, Hospital & Clinic), and Segment Forecasts, 2026 to 2035

GLP-1 biosimilars are biological medicines developed to be highly similar in quality, safety, and efficacy to the originator GLP-1 receptor agonists, such as semaglutide, liraglutide, and dulaglutide. These therapies mimic the action of the endogenous GLP-1 hormone to stimulate insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite, making them highly effective for the management of type 2 diabetes and chronic weight management.

As patents on leading branded GLP-1 drugs begin to expire, biosimilar manufacturers are advancing their pipelines to introduce more affordable alternatives. The GLP-1 biosimilars market is gaining significant momentum, driven by the global surge in obesity and type 2 diabetes prevalence, escalating healthcare costs, and the growing need for accessible treatment options. Supported by advances in biomanufacturing, evolving regulatory frameworks for biosimilar approval, and strong investment interest, GLP-1 biosimilars are poised to expand patient access to these transformative therapies while promoting cost-effective and sustainable healthcare solutions worldwide.

The GLP-1 biosimilars market is primarily driven by the rapidly increasing global prevalence of type 2 diabetes and obesity, rising demand for affordable biologic therapies, and the impending patent expirations of major originator GLP-1 drugs such as semaglutide and dulaglutide. Growing pressure on healthcare payers to reduce costs, coupled with strong clinical demand for effective weight management and glycemic control solutions, is further accelerating biosimilar adoption. 

However, the market faces notable restraints including complex and costly biosimilar development, stringent regulatory requirements for approval, manufacturing challenges related to achieving high similarity, and physician as well as patient hesitancy toward switching from established originator brands. On the opportunity front, emerging markets with large diabetic populations, increasing acceptance of biosimilars in developed countries, advancements in biomanufacturing technologies, and the potential for new indications beyond diabetes and obesity (such as cardiovascular and neurodegenerative diseases) present significant growth potential. Strategic partnerships, portfolio expansion, and the development of differentiated formulations (e.g., oral or long-acting versions) are expected to create lucrative opportunities for biosimilar manufacturers in the coming years.

Competitive Landscape

Which are the Leading Players in GLP-1 Drug Biosimilar Market?

• Teva Pharmaceutical Industries Ltd.
• Sandoz Group AG
• Biocon Biologics Ltd.
• Celltrion Inc.
• Samsung Bioepis Co., Ltd.
• Viatris Inc.
• Amgen Inc.
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited
• Intas Pharmaceuticals Ltd.
• Alvotech
• Bio-Thera Solutions Ltd.
• Organon & Co.
• Fresenius Kabi AG
• Coherus BioSciences Inc.
• Dong-A ST Co., Ltd.
• Gan & Lee Pharmaceuticals
• Hikma Pharmaceuticals PLC
• Shanghai Henlius Biotech Inc.
• Zhejiang Huahai Pharmaceutical Co., Ltd.

Market Dynamics

Driver

Increasing Demand for Affordable Diabetes and Obesity Treatments

The market for GLP-1 drug biosimilars is projected to show robust growth owing to the high prevalence of obesity and type 2 diabetes across the world. As demand for more sophisticated treatment options for metabolic disorders grows, healthcare providers are increasingly under pressure in terms of costs. Biosimilars offer a cheaper option in lieu of branded GLP-1 drugs, making treatments both accessible and affordable for patients. Additionally, the growing popularity of GLP-1 receptor agonists as treatments for obesity presents immense opportunities for biosimilar players. Increased healthcare awareness, favorable reimbursement scenarios, and expanded patient pools can be credited with driving market growth. Patent expiration of major GLP-1 drugs is also expected to fuel market expansion in the coming years.

Restrain/Challenge

Complex Regulatory Requirements and Development Costs

One of the key constraints faced by the global GLP-1 drug biosimilar market is that related to complexity in the development and approval process for biosimilars. It involves proving high levels of equivalence between the biosimilar candidate and the innovator drug in terms of efficacy, quality, and safety. This makes development more expensive and time-consuming. Besides, producing biologic drugs involves highly specialized infrastructure for production along with stringent quality standards. Moreover, intellectual property issues, exclusivity rights, and high brand loyalty among customers toward branded drugs may hamper the adoption of biosimilars in some areas.

Semaglutide Biosimilars Segment is Growing at the Highest Rate in the GLP-1 Drug Biosimilar Market In 2025, semaglutide biosimilars emerged as the fastest-growing segment in the market. The strong clinical success of semaglutide-based therapies in diabetes and obesity management has generated substantial interest among biosimilar developers. Several pharmaceutical companies are actively advancing biosimilar programs targeting this high-growth therapeutic category. The increasing global demand for weight management treatments, combined with the commercial success of reference semaglutide products, is expected to create significant opportunities for future biosimilar launches.

Injectable Pen Segment is Expected to Drive the GLP-1 Drug Biosimilar Market

The market share of the Injectable Pen segment was the largest in 2025. Injectable pens have found significant application in the use of GLP-1 drugs due to their effectiveness in treatment, precision in dosing, and easy administration. It should be mentioned that all the most effective GLP-1 drugs are currently delivered using injectable pens, which makes this type of drug delivery system more popular among healthcare professionals and patients. The increasing number of patients using once-weekly injectable products for treating diabetes and obesity may contribute to the growing segment shares during the forecast period.

Why North America Led the GLP-1 Drug Biosimilar Market?

North America emerged as the leading segment in terms of revenue share in the GLP-1 drugs biosimilars market owing to the high prevalence rates of obesity and diabetes, developed healthcare system, and rising uptake of biologics in the region. The U.S., which is among the key markets of GLP-1 drugs biosimilars, has benefited from rising expenditure on healthcare as well as the need for advanced treatments for metabolic diseases. Apart from the regulatory landscape that favors the development of biosimilars, rising cost-cutting measures in healthcare are contributing to the growth of the market.

Key Development

• In June 2024: Teva launched the first generic GLP-1 product in the U.S. market through the introduction of an authorized generic version of Victoza (liraglutide), expanding access to GLP-1 therapies for patients with type 2 diabetes.

GLP-1 Drug Biosimilar Market Report Scope: